CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T(CAR-T)细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Impact of physical and chemical parameters on spinoculation for chimeric antigen receptor T cell manufacturing using a quality-by-design approach.
Impact of physical and chemical parameters on spinoculation for chimeric antigen receptor T cell manufacturing using a quality-by-design approach.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
嵌合抗原受体(CAR)T 细胞疗法是血液系统恶性肿瘤治疗的重要进展,尤其适用于复发/难治病例。尽管临床成功,CAR-T 疗法的高成本仍是扩大应用的主要障碍。成本中相当一部分源于对病毒载体的依赖以及对转导机制理解不足。
本研究评估旋转接种过程中物理和化学参数对转导的影响。研究发现,旋转接种持续时间和转速等物理参数是转导效率的关键决定因素,可使转导率提高 20%–30%。同样,与未添加补充剂的对照条件相比,加入 LentiBOOST 和聚凝胺可将转导效率提高约 1–2 倍。鉴于物理和化学参数均影响转导效率,研究采用质量源于设计的方法系统考察二者潜在的协同或拮抗作用。该系统方法揭示聚凝胺具有细胞毒性,并表明 LentiBOOST 对促进转导至关重要,尤其是在 CD4 亚群中。优化后的流程使转导提高 2–3 倍,同时不损害 CAR-T 细胞生长或功能;该流程还兼容无血清、无异种成分培养基,支持其转化应用潜力。
Chimeric antigen receptor (CAR) T cell therapies represent a significant advancement for treating hematological malignancies, particularly in relapsed/refractory cases. Despite their clinical success, the high cost of CAR T cell therapies remains a major barrier to broader implementation. A significant proportion of these costs stems from the dependency on viral vectors and the limited understanding of transduction mechanisms. This work evaluates the impact of physical and chemical parameters during transduction using a spinoculation process. Physical parameters, such as spinoculation duration and speed, were identified as key drivers of transduction efficiency, contributing to a 20%-30% increase in transduction.
Similarly, the addition of LentiBOOST and polybrene enhanced transduction efficiency by approximately 1-2-fold compared with control conditions without these supplements. Given that both physical and chemical parameters influence transduction efficiency, a quality-by-design approach was used to systematically investigate their potential synergistic or antagonistic interactions.
This systematic approach highlighted the cytotoxic impact of polybrene and demonstrated that LentiBOOST is critical to drive transduction, particularly in CD4 subsets. The optimized process led to a 2-3-fold improvement in transduction without compromising CAR T cell growth or functionality and was shown to be compatible with serum- and xeno-free medium, supporting its translational potential.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。